CER: Top Asthma Biologic Drugs Overpriced

CER: Top Asthma Biologic Drugs Overpriced

TrialSite News reports that according to a recent ICER (Institute for Clinical and Economic Review) study, all of the major biological asthma drugs on the market are overpriced.  The analysis focused on Sanofi and Regeneron’s Nucala, Teva’s Cingair and AstraZeneca’s...

Pin It on Pinterest